Xing Shen - Lotus Pharmaceuticals VP of Corporate Devel.

LTUS Stock  USD 0.01  0.00  0.00%   

VP

Dr. Xing Shen, Ph.D., is Vice President Corporationrationrate Development of Lotus Pharmaceuticals, Inc. He was with the Company since July 2009. From July 2006 through May 2009, Mr. Shen was an associate equity analyst for RBC Capital Markets, where he cocovered approximately 30 companies in the biotech industry. Mr. Shen received a Masters of Business Administration in 2006 and a Doctorate in Molecular Cancer Biology in 2000 from Duke University. Mr. Shen received a MS in plant molecular biology from Peking University in 1995 and a BS in Virology from Wuhan University in 1992 since 2010.
Age 52
Tenure 14 years
Professional MarksCFA
Phone615 310 2688
Webhttps://lotuspharmaceuticalsusa.com
Shen has received Series 7, 63, 86 and 87 licenses from Finra and is a Chartered Financial Analyst level one candidate.

Lotus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0182 %, meaning that it created $0.0182 on every $100 dollars invested by stockholders. Lotus Pharmaceuticals' management efficiency ratios could be used to measure how well Lotus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 5.24 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lotus Pharmaceuticals has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Lotus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lotus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lotus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lotus to invest in growth at high rates of return. When we think about Lotus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

VP Age

Steven SchnitzerTortoiseEcofin Acquisition III
61
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the Peoples Republic of China. Lotus Pharmaceutical operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 233 people. Lotus Pharmaceuticals [LTUS] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Lotus Pharmaceuticals Management Team

Elected by the shareholders, the Lotus Pharmaceuticals' board of directors comprises two types of representatives: Lotus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lotus. The board's role is to monitor Lotus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lotus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lotus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Xing Shen, VP of Corporate Devel.
Yan Zeng, CFO and Principal Accounting Officer
Zhong Liu, Chairman, Founder

Lotus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lotus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lotus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lotus Pharmaceuticals' short interest history, or implied volatility extrapolated from Lotus Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lotus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Lotus Pink Sheet analysis

When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Please note, there is a significant difference between Lotus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lotus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lotus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.